💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Cameron wants assessment on Pfizer takeover bid for AstraZeneca

Published 07/05/2014, 12:32
Updated 07/05/2014, 13:17

LONDON (Reuters) - Prime Minister David Cameron said on Wednesday he wanted an assessment from MPs on U.S. drugmaker Pfizer's takeover bid for British pharmaceutical company AstraZeneca.

Cameron refused to answer directly whether he wanted to apply a public interest test to the potential merger, but he said he agreed with Business Secretary Vince Cable who said on Tuesday that Britain could apply the test.

"I absolutely agree with what the Business Secretary said yesterday but let me be clear, the most important intervention we can make is to back British jobs, British science, British R&D, British medicines and British technology," Cameron told parliament.

"The assessment that I want is from the business department on this deal," Cameron said. "And I will judge all these things about does it expand British jobs, British investment, British science."

(Reporting by William James, writing by Guy Faulconbridge, editing by Kate Holton)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.